Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CAMBRIDGE, Mass., March 01, 2017 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key March investor healthcare conferences, including the Cowen and Company 37th Annual Health Care Conference, the Goldman Sachs Third Annual Innovation Symposium, and the Oppenheimer 27th Annual Healthcare Conference.
Details of the upcoming presentations are as follows:
Wednesday, March 8th
Cowen and Company 37th Annual Health Care Conference
Who: Nessan Bermingham, Ph.D., chief executive officer & founder
Location: Boston, Massachusetts
Presentation Time: 8:40 am ET
Wednesday, March 15th
The Goldman Sachs Third Annual Innovation Symposium
Gene Editing and CRISPR Panel
Who: Nessan Bermingham, Ph.D., chief executive officer & founder
Location: New York, New York
Panel Time: 10:15 am ET
Wednesday, March 22nd
The Oppenheimer 27th Annual Healthcare Conference
Who: John Leonard, M.D., executive vice president, R&D
Location: New York, New York
Presentation Time: 2:45 pm ET
Individuals may access the presentations for available conferences via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. When available, replays of these webcasts will be available on the site for 90 days following the live events.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Senior Vice President, External Affairs & Communications +1 (857) 706-1071 [email protected] Investor Contact: Graeme Bell Chief Financial Officer +1 (857) 706-1081 [email protected]
